Search

To investigate the rates of ocular complications and visual loss and their risk factors in patients with juvenile idiopathic arthritis (JIA) -associated uveitis Medical records of 51 patients were reviewed. The incidence of visual loss to the 20/50 or worse was found to be 0026/ eye-year (EY) in the present study. Cataract and ocular hypertension occurred during the follow-up period and were significantly associated with visual acuity loss to 20/50 or worse (p =.008, HR 11.932, 95% CI 1.915–74.355; p =.03, HR 7.323, 95% CI 1.216–44.110, respectively). Anti-TNF therapy was initiated in 88.2% of our cases and 93.3% of them achieved uveitis inactivity. The risk of vision loss is higher in patients with JIA-associated uveitis who had complications at presentation. We attribute the lower complication rates and better visual outcomes in our study to the early and frequent use of biologic agents. [ABSTRACT FROM AUTHOR]

Objectives: The aim of the study was to evaluate the patients who received simultaneous subretinal tissue plasminogen activator (tPA) and bevacizumab for submacular hemorrhages secondary to neovascular age-related macular degeneration. Methods: This retrospective study included patients who underwent pars plana vitrectomy (PPV) with simultaneous subretinal tPA and subretinal bevacizumab with 18% SF6 tamponade. Anatomical and functional results of the patients before surgery and at the 1st, 6th, and 12th months after surgery, additional treatments, and complications after PPV were evaluated. Results: Eight eyes of eight patients were included in the study. The mean age of the patients was 72.38±92.3. The mean time from the onset of symptoms to treatment was 5.13±1.88 days. The patients' mean best-corrected visual acuity (BCVA) was 2.23±0.14 logMAR at baseline. Mean BCVA increased significantly at 1st, 6th, and 12th months to 1.68±0.47 logMAR, 1.58±0.49 logMAR, and 1.51±0.58 logMAR, respectively (p=0.001 at all). The mean central foveal thickness (CFT) in measurable patients was 836.8±627.02 µm at baseline. Mean CFT decreased significantly to 370.13±66.13 µm in the 1st month, 373.38±78.33 µm in the 6th month, and 367.75±116.43 µm in the 12th month (p<0.05). The maximum measurable subretinal hemorrhage height at baseline was 814.2±556.45 µm. The mean number of anti-VEGFs performed for 12 months after surgery was 4.13±2.1. At month 12, the ellipsoid zone could not be detected in 6 (75%) patients. Conclusion: Administration of subretinal bevacizumab and subretinal tPA effectively removes subretinal hemorrhage under the fovea. Intravitreal anti-VEGF treatment must be continued, as choroidal neovascular membrane activity continues after surgery. [ABSTRACT FROM AUTHOR]

Objectives: To evaluate and compare the effects of hybrid contact lenses (HCLs) and mini-scleral contact lenses (MSCLs) on visual acuity, spherical equivalent, topographic astigmatism, and higher-order aberrations (HOAs) in eyes with advanced keratoconus. Methods: We reviewed the medical records of 43 eyes of 27 patients diagnosed with advanced keratoconus fit hybrid contact lenses (AirFlex®) and mini-scleral contact lenses (Mini-misa®). Pre-fitting examinations included best corrected visual acuity (BCVA), spherical equivalent, topographic findings (topographic astigmatism, maximum keratometry, mean keratometry, central corneal thickness, thinnest corneal thickness, and corneal HOAs. Post-fitting examinations included lens corrected visual acuity, spherical equivalent, topographic astigmatism, corneal HOAs, and contact lens-related discomfort symptoms. Results: Mean BCVA (log MAR) improved significantly from 0.65±0.27 to 0.14±0.09 with HCL and 0.58±0.25 to 0.15±0.13 with MSCL (p<0.05). The mean spherical equivalent and topographic astigmatism measurements decreased significantly in both groups (p<0.05). Eight patients in the HCL group experienced lens-related discomfort. Root-mean square HOA decreased significantly in both groups (p<0.05). Conclusion: Significant improvements in visual acuity, spherical equivalent, topographic astigmatism, and HOAs were observed with both lenses. However, higher patient comfort with scleral lenses may lead to higher compliance in patients with advanced keratoconus. [ABSTRACT FROM AUTHOR]

Purpose: To develop an algorithm for the diagnosis of Behçet's disease (BD) uveitis based on ocular findings. Methods: Following an initial survey among uveitis experts, we collected multi-center retrospective data on 211 patients with BD uveitis and 207 patients with other uveitides, and identified ocular findings with a high diagnostic odds ratio (DOR). Subsequently, we collected multi-center prospective data on 127 patients with BD uveitis and 322 controls and developed a diagnostic algorithm using Classification and Regression Tree (CART) analysis and expert opinion. Results: We identified 10 items with DOR >5. The items that provided the highest accuracy in CART analysis included superficial retinal infiltrate, signs of occlusive retinal vasculitis, and diffuse retinal capillary leakage as well as the absence of granulomatous anterior uveitis or choroiditis in patients with vitritis. Conclusion: This study provides a diagnostic tree for BD uveitis that needs to be validated in future studies. [ABSTRACT FROM AUTHOR]

Axenfeld-Rieger syndrome (ARS) is a genetic disease affecting multiple organ systems. In the eye, it is associated with anterior segment dysgenesis with a high risk for glaucoma. Dental anomalies, cardiovascular malformations, hypospadias, and craniofacial abnormalities are other associated systemic conditions. Five years old monozygotic twin brothers with ARS were referred to Umraniye Training and Research Hospital, ophthalmology clinic for iris abnormalities. At presentation, pathognomonic components of ARS were found in both patients, including iris anomaly (corectopia, iris hypoplasia, and iris strands in Scwalbe’s ring), oligodontia, hypodontia, hypospadias, and periumbilical skin fold. Intraocular pressure was within normal ranges in both of the patients. Patients were followed up in the glaucoma unit. [ABSTRACT FROM AUTHOR]